Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
When Shire bought out Dyax for up to $6.5 billion in 2015, the big prize was a new drug for hereditary angioedema dubbed DX-2930 which posed a direct threat to Cinryze, a franchise drug for the rare disease player.
Thursday morning, Shire CEO Flemming Ornskov says their multi-billion dollar bet paid off with stellar Phase III data for the drug, now called lanadelumab (SHP643).
A 300 mg dose of the drug twice a month delivered an 87% reduction in mean HAE attack frequency, compared to 0% in the placebo group. It hit the primary endpoint with “highly” statistically significant results as well as all the secondaries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.